Role of prior and peri-excisional Human Papillomavirus Vaccination, including the 9-Valent vaccine, on subsequent lower genital tract dysplasia following cervical excisional surgery: A Systematic review.
DOI:
https://doi.org/10.51168/sjhrafrica.v5i12.2397Keywords:
Human papillomavirus, 9-valent HPV vaccine, Cervical excision, Loop electrosurgical excision procedure, Cervical intraepithelial neoplasia, Lower genital tract dysplasia, Secondary preventionAbstract
Background
Cervical excisional procedures, such as the loop electrosurgical excision procedure and conization, are standard treatments for high-grade cervical intraepithelial neoplasia. Despite effective lesion removal, recurrence or persistence of lower genital tract dysplasia remains a clinically relevant concern. Prophylactic human papillomavirus vaccination, particularly the 9-valent vaccine, has been proposed as a secondary preventive strategy to reduce post-treatment disease recurrence.
Objective: To systematically evaluate the effect of human papillomavirus vaccination administered prior to or around the time of cervical excisional surgery, with emphasis on the 9-valent vaccine, on subsequent lower genital tract dysplasia.
Methods
This systematic review followed PRISMA 2020 guidelines. A comprehensive search was conducted across PubMed/MEDLINE, Embase, Scopus, Web of Science, and Google Scholar. Comparative studies evaluating vaccinated versus unvaccinated women undergoing cervical excisional treatment and reporting post-treatment dysplasia outcomes were included. Owing to heterogeneity in vaccine type, vaccination timing, and outcome definitions, a qualitative narrative synthesis was performed.
Results
Seven studies met the inclusion criteria, including post-hoc analyses of randomized trials and observational cohort studies. One study specifically evaluated prior 9-valent human papillomavirus vaccination, while the remaining studies assessed quadrivalent or mixed vaccine schedules administered before or after excisional treatment. Across all studies, vaccinated women consistently demonstrated lower rates of recurrent cervical intraepithelial neoplasia grade 2 or higher, high-grade squamous intraepithelial lesions, or lower genital tract dysplasia compared with unvaccinated controls.
Conclusion
Current evidence indicates that human papillomavirus vaccination administered prior to or around cervical excisional surgery is associated with a reduced risk of subsequent lower genital tract dysplasia. While most data support peri- or post-excisional vaccination, emerging evidence suggests additional benefit with prior 9-valent vaccination.
Future research
Prospective randomized trials and large population-based cohort studies are needed to clarify optimal vaccination timing, compare vaccine valencies, and standardize post-treatment outcome assessment.
References
Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008 Jul 15;168(2):123-37. https://doi.org/10.1093/aje/kwn036 PMid:18483125 PMCid:PMC2878094
Liu Y, Ai H. Comprehensive insights into human papillomavirus and cervical cancer: Pathophysiology, screening, and vaccination strategies. Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189192. https://doi.org/10.1016/j.bbcan.2024.189192 PMid:39349261
Allanson ER, Schmeler KM. Cervical Cancer Prevention in Low- and Middle-Income Countries. Clin Obstet Gynecol. 2021 Sep 1;64(3):501-518.https://doi.org/10.1097/GRF.0000000000000629 PMid:34120126 PMCid: PMC8324570
Huang Y, Lin W, Chen X, Zheng X, Yi H, Zhang L. Analyzing and forecasting global cervical cancer burden based on WHO's elimination strategy: insights and projections from a 1990-2021 global burden of disease (GBD) study covering 204 countries and territories. J Adv Res. 2025 Sep 25:S2090-1232(25)00742-8. doi: 10.1016/j.jare.2025.09.038. Epub ahead of print. PMID: 41015178.
Ehlers U, Hoischen L, Stalp JL, Hachenberg J, Ramachandran D, Brüning B, Jentschke M, Hillemanns P, Denecke A. The treatment of cervical intraepithelial neoplasia grade 2 (HSIL): between active surveillance and surgery-a 10-year monocentric data analysis. Arch Gynecol Obstet. 2025 Oct;312(4):1125-1132. https://doi.org/10.1007/s00404-025-08097-1 PMid:40627062 PMCid:PMC12414026
Mello V, Sundstrom RK. Cervical Intraepithelial Neoplasia. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544371/
Khan MJ, Smith-McCune KK. Treatment of cervical precancers: back to basics. Obstet Gynecol. 2014 Jun;123(6):1339-1343. https://doi.org/10.1097/AOG.0000000000000287 PMid:24807323 PMCid:PMC4077778
Khunnarong J, Bunyasontikul N, Tangjitgamol S. Treatment Outcomes of Patients With Cervical Intraepithelial Neoplasia or Invasive Carcinoma Who Underwent Loop Electrosurgical Excision Procedure. World J Oncol. 2021 Aug;12(4):111-118. https://doi.org/10.14740/wjon1391 PMid:34349855 PMCid:PMC8297047
Wang XI, Huang F, Zhang S. Loop Electrosurgical Excision Procedure vs. Cold Knife Cone in Treatment of Cervical Intraepithelial Neoplasia: Review of 447 Cases. Ann Clin Lab Sci. 2017 Nov;47(6):663-667. PMID: 29263039.
Alsomali, Rawdah & wahishi, Amna & Alfaraj, Nahlah & Almutairi, Nadiyah & Almalki, Fatimah. (2025). Perioperative Nursing Care and Clinical Outcomes in Cold Knife Conization of the Cervix: Pre-Procedure Assessment, Intraoperative Support, and Postoperative Surveillance. Saudi Journal of Medicine and Public Health. 2. 2841-2852. 10.64483/202522480. https://doi.org/10.64483/202522480
Connor, J., Hartenbach, E., Glob. libr. women's med., (ISSN: 1756-2228) 2008; DOI 10.3843/GLOWM.10228
Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, Hogewoning CJ, Zaal A, Verheijen RH, Snijders PJ, Meijer CJ. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011 May;12(5):441-50. https://doi.org/10.1016/S1470-2045(11)70078-X PMid:21530398
Lili E, Chatzistamatiou K, Kalpaktsidou-Vakiani A, Moysiadis T, Agorastos T. Low recurrence rate of high-grade cervical intraepithelial neoplasia after successful excision and routine colposcopy during follow-up. Medicine (Baltimore). 2018 Jan;97(4):e9719. https://doi.org/10.1097/MD.0000000000009719 PMid:29369205 PMCid:PMC5794389
Mitta K, Tsertanidou A, Tsakiridis I, Zoubanioti E, Dagklis T, Mamopoulos A, Athanasiadis A, Kalogiannidis I. Risk factors related to recurrence after surgical excision procedure for cervical dysplasia. Hippokratia. 2023 Oct-Dec;27(4):132-140. PMID: 39372323; PMCID: PMC11451503.
Frega A, Sopracordevole F, Scirpa P, Biamonti A, Lorenzon L, Scarani S, De Sanctis L, Pacchiarotti A, Moscarini M, French D. The re-infection rate of high-risk HPV and the recurrence rate of vulvar intraepithelial neoplasia (VIN) usual type after surgical treatment. Med Sci Monit. 2011 Sep;17(9):CR532-5. https://doi.org/10.12659/MSM.881941 PMid:21873951 PMCid:PMC3560503
Na J, Li Y, Lu Q, Wang Y, Han S, Wang J. Investigating the impact of persistent HPV infection on recurrence of lesions post-surgery for early-stage cervical cancer and related influencing factors. Front Oncol. 2025 Feb 4;15:1506521. https://doi.org/10.3389/fonc.2025.1506521 PMid:39968075 PMCid:PMC11832401
Khairkhah N, Bolhassani A, Najafipour R. Current and future direction in treatment of HPV-related cervical disease. J Mol Med (Berl). 2022 Jun;100(6):829-845. https://doi.org/10.1007/s00109-022-02199-y PMid:35478255 PMCid:PMC9045016
Huber J, Mueller A, Sailer M, Regidor PA. Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite. Women's Health (Lond). 2021 Jan-Dec;17:17455065211020702. https://doi.org/10.1177/17455065211020702 PMid:34096424 PMCid:PMC8785287
Huiling Ni, Canhua Huang, Zhi Ran, Shan Li, Chunmei Kuang, Yu Zhang, Kai Yuan, Targeting HPV for the prevention, diagnosis, and treatment of cervical cancer, Journal of Molecular Cell Biology, Volume 16, Issue 10, October 2024, mjae046, https://doi.org/10.1093/jmcb/mjae046 PMid:39402008 PMCid: PMC12080229
Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J, Xu Y, Qian C. Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives. Front Cell Infect Microbiol. 2022 Jul 4;12:909223. https://doi.org/10.3389/fcimb.2022.909223 PMid:35860379 PMCid:PMC9289603
Poljak M. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges. Clin Microbiol Infect. 2012 Oct;18 Suppl 5:64-9. https://doi.org/10.1111/j.1469-0691.2012.03946.x PMid:22862799
Luckett R, Feldman S. Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. Hum Vaccin Immunother. 2016 Jun 2;12(6):1332-42. https://doi.org/10.1080/21645515.2015.1108500 PMid:26588179 PMCid:PMC4964711
Bhalerao V, Gotarkar S, Muneshwar K. The Impact of HPV Vaccination on Cervical Cancer in adolescent females: A narrative review. J Family Med Prim Care. 2024 Nov;13(11):4775-4782. https://doi.org/10.4103/jfmpc.jfmpc_235_24 PMid:39722908 PMCid:PMC11668371
Md.Rezaul Islam, Abdur Rauf, Most.Nazmin Aktar, Md Naeem Hossain Fakir, Sadiya Islam Trisha, Asraful Islam Asif, Md.Harun Or Rashid, Md.Ibrahim Khalil Al-Imran, Gazi Kaifeara Thufa, Farhana Prodhan Emu, Hassan A. Hemeg, Hanan A. Ogaly, Rekha Thiruvengadam, Seung-Hyun Kim, Muthu Thiruvengadam, Recent advances in human papillomavirus vaccines and therapeutic strategies: Combating cervical and non-cervical cancers, Genes & Diseases, 2025, 101880, ISSN 2352-3042, https://doi.org/10.1016/j.gendis.2025.101880.
Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JC, Rohan TE, Villa LL, Franco EL. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 2010 Nov 1;70(21):8569-77. https://doi.org/10.1158/0008-5472.CAN-10-0621 PMid:20978200 PMCid:PMC4068337
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. https://doi.org/10.1136/bmj.n71 PMid:33782057 PMCid: PMC8005924
Joura E, Kjaer SK, Bautista O, Luxembourg A, Saah A, Giuliano A. Effect of Prior 9-Valent Human Papillomavirus Vaccination on Subsequent Lower Genital Tract Dysplasia After Cervical Excisional Surgery. Obstet Gynecol. 2026 Jan 1;147(1):73-82. https://doi.org/10.1097/AOG.0000000000006113 PMid:41166720 PMCid:PMC12704676
Petráš M, Lomozová D, Dvořák V, Dvořák V Jr, Malinová J, Trnková M, Fišer I, Dlouhý P, Rosina J, Lesná IK. Early and long-term effects of prophylactic and post-excision human papillomavirus vaccination on recurrent high-grade cervical intraepithelial neoplasia relative to margin status: a retrospective cohort study in the Czech Republic. Lancet Reg Health Eur. 2025 Jun 3;55:101337. https://doi.org/10.1016/j.lanepe.2025.101337 PMid:40525201 PMCid:PMC12167485
Chen M, Li C, Cui Q, Zhou C, Chen P, Yao S. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: A prospective observational study in China. Eur J Obstet Gynecol Reprod Biol. 2023 Jul;286:10-15. https://doi.org/10.1016/j.ejogrb.2023.04.014 PMid:37159990
Gómez de la Rosa AG, Quesada López-Fe A, Vilar Chesa M, Ferrer Machín A, Gimeno Gil A, Molina Bethancourt A, García Bello MÁ, Pérez-Méndez LI. Efficacy of Human Papillomavirus Vaccination 4 Years After Conization for High-Grade Cervical Neoplasia. J Low Genit Tract Dis. 2021 Oct 1;25(4):287-290. https://doi.org/10.1097/LGT.0000000000000625 PMid:34456270
Del Pino M, Martí C, Torras I, Henere C, Munmany M, Marimon L, Saco A, Torné A, Ordi J. HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions. Vaccines (Basel). 2020 May 23;8(2):245. https://doi.org/10.3390/vaccines8020245 PMid:32456136 PMCid:PMC7349984
Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A, Svelato A, Bertacca G, Lombardi S, Joura EA. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol Oncol. 2018 Nov;151(2):229-234. https://doi.org/10.1016/j.ygyno.2018.08.033 PMid:30197061
Kang WD, Choi HS, Kim SM. Is vaccination with the quadrivalent HPV vaccine after a loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol. 2013 Aug;130(2):264-8. https://doi.org/10.1016/j.ygyno.2013.04.050 PMid:23623831
Casajuana-Pérez A, Ramírez-Mena M, Ruipérez-Pacheco E, Gil-Prados I, García-Santos J, Bellón-Del Amo M, Hernández-Aguado JJ, de la Fuente-Valero J, Zapardiel I, Coronado-Martín PJ. Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study. Vaccines (Basel). 2022 Feb 14;10(2):288.https://doi.org/10.3390/vaccines10020288 PMid:35214747 PMCid:PMC8879017
Jentschke M, Kampers J, Becker J, Sibbertsen P, Hillemanns P. Prophylactic HPV vaccination after conization: A systematic review and meta-analysis. Vaccine. 2020 Sep 22;38(41):6402-6409. https://doi.org/10.1016/j.vaccine.2020.07.055 PMid:32762871
Bartels HC, Postle J, Rogers AC, Brennan D. Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis. Int J Gynecol Cancer. 2020 Jun;30(6):777-782. doi: 10.1136/ijgc-2020-001197. Epub 2020 Apr 9. Erratum in: Int J Gynecol Cancer. 2020 Jul;30(7):1085-1086. https://doi.org/10.1136/ijgc-2020-001197corr1 PMid:32487687
Di Donato V, Caruso G, Petrillo M, Kontopantelis E, Palaia I, Perniola G, Plotti F, Angioli R, Muzii L, Benedetti Panici P, Bogani G. Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis. Vaccines (Basel). 2021 Apr 21;9(5):410. https://doi.org/10.3390/vaccines9050410 PMid:33919003 PMCid:PMC8143003
Eriksen DO, Jensen PT, Schroll JB, Hammer A. Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2022 Jun;101(6):597-607. https://doi.org/10.1111/aogs.14359 PMid:35470865 PMCid:PMC9564558
Lichter K, Krause D, Xu J, Tsai SHL, Hage C, Weston E, Eke A, Levinson K. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis. Obstet Gynecol. 2020 May;135(5):1070-1083. doi: 10.1097/AOG.0000000000003833. Erratum in: Obstet Gynecol. 2020 Jun;135(6):1489. doi: 10.1097/AOG.0000000000003937. PMID: 32282601.
Sand FL, Kjaer SK, Frederiksen K, Dehlendorff C. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int J Cancer. 2020 Aug 1;147(3):641-647. https://doi.org/10.1002/ijc.32752 PMid:31648368
Dvořák V, Petráš M, Dvořák V, Lomozová D, Dlouhý P, Králová Lesná I, Pilka R. Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: Retrospective cohort study. Hum Vaccin Immunother. 2024 Dec 31;20(1):2343552. https://doi.org/10.1080/21645515.2024.2343552 PMid:38723789 PMCid:PMC11086040
Sørbye, S. W., Antonsen, M., & Richardsen, E. (2026). HPV Vaccination and HPV Outcomes After LEEP: A Retrospective Population-Based Cohort Study from Northern Norway, 2022-2024. Vaccines, 14(1), 44. https://doi.org/10.3390/vaccines14010044 PMid:41600960 PMCid:PMC12846414
Reuschenbach M, Doorbar J, Del Pino M, Joura EA, Walker C, Drury R, Rauscher A, Saah AJ. Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer. Vaccine. 2023 Oct 6;41(42):6194-6205. https://doi.org/10.1016/j.vaccine.2023.08.047 PMid:37704498
Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, Stanley MA, Franceschi S. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016 Dec 1;2:16086.https://doi.org/10.1038/nrdp.2016.86 PMid:27905473
Rykkelid M, Wennberg HM, Richardsen E, Sørbye SW. Post-Conization HPV Vaccination and Its Impact on Viral Status: A Retrospective Cohort Study in Troms and Finnmark, 2022. Pathogens. 2024 May 2;13(5):381. https://doi.org/10.3390/pathogens13050381 PMid:38787233 PMCid:PMC11124440
Palumbo M, Lavitola G, Di Filippo C, Foreste V, Granata M, Imperatore O, Ascione M, Della Corte L, Bifulco G. Impact of Human papillomavirus 9-valent vaccine on viral clearance after surgical treatment: A single-center retrospective observational study. Eur J Obstet Gynecol Reprod Biol. 2025 Jun;310:113994. doi: 10.1016/j.ejogrb.2025.113994. Epub 2025 Apr 20. PMID: 40267822.
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Erratum in: The Lancet. 2010 Sep 25;376(9746):1054. PMID: 19586656.
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915-27. https://doi.org/10.1056/NEJMoa061741 PMid:17494925
Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, Pan QJ, Zhang WH, Zhao FH, Zhang CF, Yang X, Yu JX, Zhu J, Zhu Y, Chen F, Zhang Q, Wang H, Wang C, Bi J, Xue S, Shen L, Zhang YS, He Y, Tang H, Karkada N, Suryakiran P, Bi D, Struyf F. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial. Cancer Med. 2019 Oct;8(14):6195-6211.https://doi.org/10.1002/cam4.2399 PMid:31305011 PMCid:PMC6797633
Drolet M, Bénard É, Pérez N, Brisson M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019 Aug 10;394(10197):497-509. doi: 10.1016/S0140-6736(19)30298-3. Epub 2019 Jun 26. PMID: 31255301; PMCID: PMC7316527.
Cao Q, Hou Y, Wang C, Yin J. Effect of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: A systematic review and meta-analysis. PLoS One. 2024 Dec 31;19(12):e0312128. https://doi.org/10.1371/journal.pone.0312128 PMid:39739895 PMCid:PMC11687797
Sharpless, Kathryn E. MD, PhD1; Marcus, Jenna Z. MD2; Kuroki, Lindsay M. MD, MSCI3; Wiser, Amy L. MD4; Flowers, Lisa MD, MPH5. ASCCP Committee Opinion: Adjuvant Human Papillomavirus Vaccine for Patients Undergoing Treatment for Cervical Intraepithelial Neoplasia. Journal of Lower Genital Tract Disease 27(1):p 93-96, January 2023. https://doi.org/10.1097/LGT.0000000000000703 PMid:36538783 PMCid:PMC9770105
American College of Obstetricians and Gynecologists (ACOG). Adjuvant HPV vaccination for patients undergoing treatment for CIN2+. Practice Advisory. 2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Dr.Suvarna Palanivelu, Dr.Karthik Shunmugavelu
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
